Time course and dose effect of metformin on weight in patients with different disease states

References

• Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Curr Diab Rep. 2017 Jan;17(1):5.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Jan;38(1):140–149.
   PubMed Web of Science ®Google Scholar
• Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract. 2018 Sep;143:409–419.
   PubMed Web of Science ®Google Scholar
• Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc. 2014 Dec;3(6):e001202.
   PubMed Web of Science ®Google Scholar
• Dei Cas A, Spigoni V, Ridolfi V, et al. Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach. Endocr Metab Immune Disord Drug Targets. 2013 Mar;13(1):38–50.
   PubMed Web of Science ®Google Scholar
• Romero R, Erez O, Huttemann M, et al. Metformin, the aspirin of the 21st century: its role in gestational diabetes mellitus, prevention of preeclampsia and cancer, and the promotion of longevity. Am J Obstet Gynecol. 2017 Sep;217(3):282–302.
   PubMed Web of Science ®Google Scholar
• Takiyama Y, Harumi T, Watanabe J, et al. Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1alpha expression and oxygen metabolism. Diabetes. 2011 Mar;60(3):981–992.
   PubMed Web of Science ®Google Scholar
• Negrotto L, Farez MF, Correale J. Immunologic effects of metformin and pioglitazone treatment on metabolic syndrome and multiple sclerosis. JAMA Neurol. 2016 May 1;73(5):520–528.
   PubMed Web of Science ®Google Scholar
• Yousef M, Tsiani E. Metformin in lung cancer: review of in vitro and in vivo animal studies. Cancers (Basel). 2017 May 6;9:5.
   Web of Science ®Google Scholar
• Lin J, Gill A, Zahm SH, et al. Metformin use and survival after non-small cell lung cancer: a cohort study in the US military health system. Int J Cancer. 2017 July 15;141(2):254–263.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park CH, Eun CS, et al. Metformin use and the risk of colorectal adenoma: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2017 May;32(5):957–965.
   PubMed Web of Science ®Google Scholar
• Liu F, Yan L, Wang Z, et al. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. Oncotarget. 2017 Feb 28;8(9):16017–16026.
   PubMedGoogle Scholar
• Chen X, Li C, He T, et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer Biol Ther. 2016 May 3;17(5):507–514.
   PubMed Web of Science ®Google Scholar
• Zhang J, Li G, Chen Y, et al. Metformin inhibits tumorigenesis and tumor growth of breast cancer cells by upregulating miR-200c but downregulating AKT2 expression. J Cancer. 2017;8(10):1849–1864.
   PubMed Web of Science ®Google Scholar
• Chen K, Qian W, Jiang Z, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer. 2017 July 24;16(1):131.
   PubMedGoogle Scholar
• Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998 Jan;6(1):47–53.
   PubMedGoogle Scholar
• Out M, Miedema I, Jager-Wittenaar H, et al. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: a post hoc analysis of a randomized placebo-controlled 4.3-year trial. Diabetes Obes Metab. 2018 Jan;20(1):219–223.
   PubMed Web of Science ®Google Scholar
• Wu H, Esteve E, Tremaroli V, et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat Med. 2017 July;23(7):850–858.
   PubMed Web of Science ®Google Scholar
• Esteghamati A, Eskandari D, Mirmiranpour H, et al. Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: a randomized clinical trial. Clin Nutr. 2013 Apr;32(2):179–185.
   PubMed Web of Science ®Google Scholar
• Chen CH, Huang MC, Kao CF, et al. Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2013 May;74(5):e424–30.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. Jama. 2008 Jan 9;299(2):185–193.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernandez V, et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res. 2007 July;93(1–3):99–108.
   PubMed Web of Science ®Google Scholar
• Wu RR, Jin H, Gao K, et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2012 Aug;169(8):813–821.
   PubMed Web of Science ®Google Scholar
• Wang M, Tong JH, Zhu G, et al. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study. Schizophr Res. 2012 June;138(1):54–57.
   PubMed Web of Science ®Google Scholar
• Jarskog LF, Hamer RM, Catellier DJ, et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry. 2013 Sep;170(9):1032–1040.
   PubMed Web of Science ®Google Scholar
• Rado J, von Ammon Cavanaugh S. A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. J Clin Psychopharmacol. 2016 Apr;36(2):163–168.
   PubMed Web of Science ®Google Scholar
• Klein DJ, Cottingham EM, Sorter M, et al. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry. 2006 Dec;163(12):2072–2079.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Guo XF, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry. 2008 Mar;165(3):352–358.
   PubMed Web of Science ®Google Scholar
• Peng PJ, Ho PS, Tsai CK, et al. A pilot study of randomized, head-to-head of metformin versus topiramate in obese people with schizophrenia. Clin Neuropharmacol. 2016 Nov/Dec;39(6):306–310.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhang FY, Gao KM, et al. Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials. Mol Psychiatry. 2016 Nov;21(11):1537–1544.
   PubMed Web of Science ®Google Scholar
• Chiu CC, Lu ML, Huang MC, et al. Effects of low dose metformin on metabolic traits in clozapine-treated schizophrenia patients: an exploratory twelve-week randomized, double-blind, placebo-controlled study. PloS One. 2016;11(12):e0168347.
   PubMed Web of Science ®Google Scholar
• Carrizo E, Fernandez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009 Aug;113(1):19–26.
   PubMed Web of Science ®Google Scholar
• Yanovski JA, Krakoff J, Salaita CG, et al. Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial. Diabetes. 2011 Feb;60(2):477–485.
   PubMed Web of Science ®Google Scholar
• Pastor-Villaescusa B, Canete MD, Caballero-Villarraso J, et al. Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial. Pediatrics. 2017 July;140:1.
   Web of Science ®Google Scholar
• Mauras N, DelGiorno C, Hossain J, et al. Metformin use in children with obesity and normal glucose tolerance–effects on cardiovascular markers and intrahepatic fat. J Pediatr Endocrinol Metab. 2012;25(1–2):33–40.
   PubMed Web of Science ®Google Scholar
• Lim SS, Norman RJ, Clifton PM, et al. The effect of comprehensive lifestyle intervention or metformin on obesity in young women. Nutr Metab Cardiovasc Dis. 2011 Apr;21(4):261–268.
   PubMed Web of Science ®Google Scholar
• Yerevanian A, Soukas AA. Metformin: mechanisms in human obesity and weight loss. Curr Obes Rep. 2019 June;8(2):156–164.
   PubMed Web of Science ®Google Scholar
• Wilcock C, Bailey CJ. Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994 Jan;24(1):49–57.
   PubMed Web of Science ®Google Scholar
• Gontier E, Fourme E, Wartski M, et al. High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008 Jan;35(1):95–99.
   PubMed Web of Science ®Google Scholar
• Coll AP, Chen M, Taskar P, et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. 2020 Feb;578(7795):444–448.
   PubMed Web of Science ®Google Scholar
• Wu J, Xu L, Lv Y, et al. Quantitative analysis of efficacy and associated factors of calcium intake on bone mineral density in postmenopausal women. Osteoporos Int. 2017 June;28(6):2003–2010.
   PubMed Web of Science ®Google Scholar
• Mould DR. Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther. 2012 Sep;92(3):283–286.
   PubMed Web of Science ®Google Scholar
• Dong Z, Xu L, Liu H, et al. Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines. Obesity Rev. 2017 Dec;18(12):1377–1385.
   PubMed Web of Science ®Google Scholar
• Dong L, Xu L, Li Y, et al. Model-based comparing efficacy of fluoxetine between elderly and non-elderly participants with major depressive disorder. J Affect Disord. 2018 Mar;15(229):224–230.
   Google Scholar
• Zhuo C, Xu Y, Liu S, et al. Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. Front Pharmacol. 2018;9:1393.
   PubMed Web of Science ®Google Scholar
• Piera-Mardemootoo C, Lambert P, Faillie JL. Efficacy of metformin on glycemic control and weight in drug-naive type 2 diabetes mellitus patients: a systematic review and meta-analysis of placebo-controlled randomized trials. Therapie. 2018 Feb 21:S0040-5957(18)30019-2. DOI: 10.1016/j.therap.2018.01.006. Epub ahead of print.
   PubMedGoogle Scholar
• de Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016 Oct 3;16(1):341.
   PubMedGoogle Scholar
• Cheng Q, Huang J, Xu L, et al. Analysis of time-course, dose-effect, and influencing factors of antidepressants in the treatment of acute adult patients with major depression. Int J Neuropsychopharmacol. 2020 Feb 1;23(2):76–87.
   PubMed Web of Science ®Google Scholar
• Boucher M, Bennetts M. The many flavors of model-based meta-analysis: part I-introduction and landmark data. CPT Pharmacometrics Syst Pharmacol. 2016 Feb;5(2):54–64.
   PubMedGoogle Scholar
• Staud F, Cerveny L, Ahmadimoghaddam D, et al. Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics. Int J Biochem Cell Biol. 2013 Sep;45(9):2007–2011.
   PubMed Web of Science ®Google Scholar
• Han TK, Proctor WR, Costales CL, et al. Four cation-selective transporters contribute to apical uptake and accumulation of metformin in Caco-2 cell monolayers. J Pharmacol Exp Ther. 2015 Mar;352(3):519–528.
   PubMed Web of Science ®Google Scholar
• Zhou M, Xia L, Wang J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (Plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos. 2007 Oct;35(10):1956–1962.
   PubMed Web of Science ®Google Scholar
• Muller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851–1860.
   PubMed Web of Science ®Google Scholar
• Stage TB, Wellhagen G, Christensen MMH, et al. Using a semi-mechanistic model to identify the main sources of variability of metformin pharmacokinetics. Basic Clin Pharmacol Toxicol. 2019 Jan;124(1):105–114.
   PubMed Web of Science ®Google Scholar